Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06654726
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-22
Brief Title:
A Multi-center Evaluation of Aldafermin in a Randomized Double-blind Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2b3 Multicenter Randomized Double-blind Placebo-controlled Study to Assess the Efficacy Safety and Tolerability of Aldafermin in Subjects With Primary Sclerosing Cholangitis ALPINE-PSC
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ALPINE-PSC
Brief Summary:
A multi-center evaluation of aldafermin in a randomized double-blind placebo-controlled study in subjects with Primary Sclerosing Cholangitis
Detailed Description:
Evaluation of Efficacy Safety and Tolerability of Aldafermin in a Phase 2b3 Randomized Double-blind Placebo-controlled Multi-center Study in Subjects with Primary Sclerosing Cholangitis ALPINE-PSC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None